HIV's infiltration of the brain leads to chronic inflammation and cognitive decline, as the virus persists in immune cells called helper T cells. While antiviral drugs can control HIV, they do not effectively reach the brain. A recent study, conducted by researchers from UC Davis and the University of Pittsburgh, revealed that therapies aimed at reducing brain inflammation can backfire by increasing viral levels. This occurs when blocking the alpha-4 integrin, which facilitates T cell migration into the brain, reduces killer T cells that eliminate infected cells. Consequently, helper T cells continue to transport HIV into the brain, exacerbating the infection. The findings highlight the necessity for more precise HIV treatments that can mitigate neurodegeneration without causing additional harm. With over 40 million people living with HIV globally, and many lacking treatment access, there is a pressing need for enhanced research and funding to improve therapeutic strategies against HIV and related diseases.